The protective effect of Ursodeoxycholic Acid in prevention of hepatic damage in neurological patients treated with Sodium Valporat

Phase 3

Recruiting

• Conditions: Condition 1: Migraine. Condition 2: Epilepsy. Condition 3: Bipolar disorder.; Migraine; Epilepsy and recurrent seizures; Bipolar disorder

• Registration Number: IRCT20181228042156N1
• Lead Sponsor: Zabol University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 May 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

Willing to participate in the study
Definite diagnosis of migraine, bipolar disorder, or epilepsy
Age of <18 years
Not being pregnant or lactating

Exclusion Criteria

Not willing to participate in the study
Systemic diseases, acute or chronic hepatic diseases (hepatitis B, C, cirrhosis), diabetes, celiac, hypertension, cardiovascular diseases, pulmonary diseases, renal diseases
Age > 18 years old
Using hepatotoxic drugs and antibiotics
Not taking more than 10% of the administrated Ursodeoxycholic Acid

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Abnormal liver functional tests. Timepoint: The outcomes are measured 3, 6, and 9 months after the initiation of the intervention. Method of measurement: Using serum separated from venous blood and ELISA method.